Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532651 | 0.87 | PKM (0.54) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL10261881 | 0.86 | CYP2C19 (0.62) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL28668720 | 0.82 | PKM (0.48) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL23780914 | 0.80 | LMNA (0.49) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL29137225 | 0.80 | ALDH1A1 (0.45) | PKMHTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17155022 | 0.78 | CYP2C19 (0.49) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL4537086 | 0.76 | PKM (0.88) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL565301 | 0.76 | PKM (0.88) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL1711115 | 0.76 | PKM (0.85) | PKMHTTALDH1A1POLBLMNA | |
| SCHEMBL10724066 | 0.76 | PKM (0.88) | PKMHTTALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | PKM 1342/4885HTT 4566/4885ALDH1A1 3712/4885 |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PKM 1342/4885HTT 4566/4885ALDH1A1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.